SCHEMBL2236374

SCHEMBL2236374

COc1cc(OC)c(Cl)c(NC(=O)c2csc3c(Nc4ccc(F)c(Cl)c4)ncnc23)c1Cl

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 3/20 0.58
CSF1R P07333 3/20 0.58
BRAF P15056 3/20 0.58
DDR1 Q08345 3/20 0.58
DDR2 Q16832 3/20 0.58
EGFR P00533 8/20 0.49
ERBB2 P04626 4/20 0.49
CD38 P28907 1/20 0.48
KDR P35968 3/20 0.48
AURKA O14965 2/20 0.48
INSR P06213 1/20 0.48
FBP1 P09467 1/20 0.48
PDGFRB P09619 1/20 0.48
FLT4 P35916 1/20 0.48
CLK1 P49759 1/20 0.48
EPHB4 P54760 1/20 0.48
TEK Q02763 1/20 0.48
AURKB Q96GD4 1/20 0.48
ERBB4 Q15303 1/20 0.47
FLT1 P17948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125273 0.96 RAF1 (0.60) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2232899 0.89 RAF1 (0.56) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2234812 0.88 RAF1 (0.56) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL14137205 0.87 BRAF (0.51) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL14125256 0.86 RAF1 (0.55) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2232963 0.86 BRAF (0.48) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2232574 0.86 RAF1 (0.48) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2232775 0.85 RAF1 (0.46) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL14125203 0.83 RAF1 (0.58) RAF1CSF1RBRAFDDR1DDR2
SCHEMBL2303933 0.83 KDR (0.49) RAF1CSF1RBRAFDDR1DDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP disclosed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US disclosed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP disclosed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP disclosed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US disclosed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 RAF1 130/4885CSF1R 4274/4885BRAF 113/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 RAF1 130/4885CSF1R 4274/4885BRAF 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.